Hilal Bacanak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hilal Bacanak has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Akito Nagatsu
College of Pharmacy, Department of Pharmacognosy, Kinjo Gakuin University, Nagoya, 463‑8521, Japan
2 shared publications - Esra Küpeli Akkol
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Etiler, Ankara 06330, Türkiye
2 shared publications - Zeynep Dogan
Faculty of Pharmacy, Department of Pharmacognosy, Hacettepe University, Ankara, 06100, Türkiye
2 shared publications - Emre Tunçel
Republic of Turkey Ministry of Health Turkish Medicines and Medical Devices Agency Ankara Türkiye
1 shared publication - Eren Aytekin
Department of Pharmaceutical Technology, Faculty of Pharmacy Hacettepe University Ankara Türkiye
1 shared publication - Heybet Kerem Polat
Republic of Turkey Ministry of Health, Turkish Medicines And Medical Devices Agency
1 shared publication
Latest Publications
- Open Access
- 2 August 2026
- Published by Wiley in Journal of the Science of Food and Agriculture
From nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients
Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences. By combining various polymers with active herbal ingredients, these systems mimic the natural extracellular matrix and provide improved functions such as a high surface area‐to‐volume ratio, drug targeting, and controlled drug release. Preclinical studies demonstrate that phytochemical‐containing nanofibers have improved therapeutic profiles, including higher anti‐inflammatory, antioxidant, antimicrobial, and antineoplastic effects. In various biomedical applications, such as promoting tissue engineering (such as bone and nerve regeneration), limiting tumor growth, and accelerating wound closure, it was shown that nanofibers may overcome the physicochemical limitations of herbal drugs such as low solubility and bioavailability. Despite promising preclinical study results, there are significant obstacles in the way of the commercialization of herbal drug‐loaded nanofibers. The difficult standardization of multi‐component herbal extracts, stabilization drawbacks, and the absence of scalable industrial manufacturing equipment that can maintain repeatable characterization of nanofibers are some of the major obstacles, in addition to a lack of clinical trials. To navigate the clinical translation of nanofibers, interdisciplinary collaboration regarding quality control, safety, and regulatory pathways is strictly necessary due to the case‐by‐case review approach utilized by regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review offers a comprehensive overview of research on herbal drug‐loaded nanofibers and contributes a novel perspective with regulatory and clinical translational insights. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 2 August 2026
- Published by Wiley in Journal of the Science of Food and Agriculture
Open AccessFrom nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients
Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences. By combining various polymers with active herbal ingredients, these systems mimic the natural extracellular matrix and provide improved functions such as a high surface area‐to‐volume ratio, drug targeting, and controlled drug release. Preclinical studies demonstrate that phytochemical‐containing nanofibers have improved therapeutic profiles, including higher anti‐inflammatory, antioxidant, antimicrobial, and antineoplastic effects. In various biomedical applications, such as promoting tissue engineering (such as bone and nerve regeneration), limiting tumor growth, and accelerating wound closure, it was shown that nanofibers may overcome the physicochemical limitations of herbal drugs such as low solubility and bioavailability. Despite promising preclinical study results, there are significant obstacles in the way of the commercialization of herbal drug‐loaded nanofibers. The difficult standardization of multi‐component herbal extracts, stabilization drawbacks, and the absence of scalable industrial manufacturing equipment that can maintain repeatable characterization of nanofibers are some of the major obstacles, in addition to a lack of clinical trials. To navigate the clinical translation of nanofibers, interdisciplinary collaboration regarding quality control, safety, and regulatory pathways is strictly necessary due to the case‐by‐case review approach utilized by regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review offers a comprehensive overview of research on herbal drug‐loaded nanofibers and contributes a novel perspective with regulatory and clinical translational insights. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- Open Access
- 29 April 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Phytochemical investigation and evaluation of anti-inflammatory and wound healing activities of Plantago major subsp. intermedia (Gilib.) Lange
Background: Plantago major subsp. intermedia has been traditionally used in Türkiye for the treatment of wounds, abscesses, constipation, pain, ulcers, hemorrhoids and gynecological diseases. In the present study, the phytochemical composition of P. major subsp. intermedia (Gilib.) Lange was investigated and its anti-inflammatory and wound healing effects were examined in light of existing experimental evidence from related Plantago species. Methods: MeOH, 80% EtOH and water extracts of the plant were prepared. In vivo anti-inflammatory effects of these extracts were investigated using an acetic acid-induced capillary permeability model and their wound healing effects were studied using linear incision and circular excision wound models. Isolation studies were performed on the 80% EtOH extract. Furthermore, in vitro studies were conducted on the 80% EtOH extract, the main fractions obtained from this extract and the some of the isolated pure compounds. In these in vitro studies, anti-inflammatory effects were investigated by measuring nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α ) levels and wound healing effects were investigated using the scratch test. Results: A total of six compounds were isolated from P. major subsp. intermedia : Isotachioside (1), aucubin (2), 10-hydroxymajoroside (3), 10-acetoxymajoroside (4), martynoside (5) and acteoside (6). All tested compounds significantly inhibited NO production at concentrations of 25, 50 and 100 µM (12.68%-61.89%). Although in vivo results were not statistically significant, the 80% EtOH extract showed the highest efficacy in linear incision and circular excision wound models. Conclusions: The results of this study indicate the in vitro anti-inflammatory and wound healing activities of P. major subsp. intermedia and are consistent with previously reported biological activities of P. major .
- 29 April 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Open AccessPhytochemical investigation and evaluation of anti-inflammatory and wound healing activities of Plantago major subsp. intermedia (Gilib.) Lange
Background: Plantago major subsp. intermedia has been traditionally used in Türkiye for the treatment of wounds, abscesses, constipation, pain, ulcers, hemorrhoids and gynecological diseases. In the present study, the phytochemical composition of P. major subsp. intermedia (Gilib.) Lange was investigated and its anti-inflammatory and wound healing effects were examined in light of existing experimental evidence from related Plantago species. Methods: MeOH, 80% EtOH and water extracts of the plant were prepared. In vivo anti-inflammatory effects of these extracts were investigated using an acetic acid-induced capillary permeability model and their wound healing effects were studied using linear incision and circular excision wound models. Isolation studies were performed on the 80% EtOH extract. Furthermore, in vitro studies were conducted on the 80% EtOH extract, the main fractions obtained from this extract and the some of the isolated pure compounds. In these in vitro studies, anti-inflammatory effects were investigated by measuring nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α ) levels and wound healing effects were investigated using the scratch test. Results: A total of six compounds were isolated from P. major subsp. intermedia : Isotachioside (1), aucubin (2), 10-hydroxymajoroside (3), 10-acetoxymajoroside (4), martynoside (5) and acteoside (6). All tested compounds significantly inhibited NO production at concentrations of 25, 50 and 100 µM (12.68%-61.89%). Although in vivo results were not statistically significant, the 80% EtOH extract showed the highest efficacy in linear incision and circular excision wound models. Conclusions: The results of this study indicate the in vitro anti-inflammatory and wound healing activities of P. major subsp. intermedia and are consistent with previously reported biological activities of P. major .
- Open Access
Bioactive Metabolites from Aerial Parts of Plantago indica L.: Structural Elucidation and Integrated In Vitro/In Vivo Assessment of Anti-Inflammatory and Wound-Healing Efficacy
The genus Plantago (Plantaginaceae) is widely distributed worldwide. The Plantago species are used in traditional medicine as wound healers, anti-inflammatory agents, antipyretics, and analgesics. This study aimed to investigate the phytochemical composition from the aerial parts of Plantago indica L. and to evaluate its biological activities. Isolation studies and in vitro investigations were conducted on an aqueous phase of 80% EtOH extract of Plantago indica. In addition, in vivo studies were carried out using the MeOH, 80% EtOH, and water extracts. Plantarenaloside (1), 3-oxo-α-ionol β-glucoside (2), martynoside (3), acteoside (4), feruloyl gardoside (5), and ursolic acid (6) were isolated from the extract. The structures of the compounds were elucidated using 1D- and 2D-NMR and ESI-MS analyses. The extract, fractions, and pure compounds were tested in vitro for cytotoxicity (MTT), anti-inflammatory activity (NO, IL-6, and TNF-α production), wound healing (scratch test), and antioxidant capacity (DPPH, ABTS, SO). Feruloyl gardoside (20.11–58.27%) significantly reduced NO levels at concentrations of 25–100 µM. It significantly reduced IL-6 levels (40.17%) at 100 µM. Additionally, the in vivo anti-inflammatory (acetic acid-induced vascular permeability) and wound healing (incision and excision models) effects of the extracts were investigated. The findings suggest that P. indica may be considered to be a potential therapeutic option for managing inflammation and for promoting wound healing.
Open AccessBioactive Metabolites from Aerial Parts of Plantago indica L.: Structural Elucidation and Integrated In Vitro/In Vivo Assessment of Anti-Inflammatory and Wound-Healing Efficacy
The genus Plantago (Plantaginaceae) is widely distributed worldwide. The Plantago species are used in traditional medicine as wound healers, anti-inflammatory agents, antipyretics, and analgesics. This study aimed to investigate the phytochemical composition from the aerial parts of Plantago indica L. and to evaluate its biological activities. Isolation studies and in vitro investigations were conducted on an aqueous phase of 80% EtOH extract of Plantago indica. In addition, in vivo studies were carried out using the MeOH, 80% EtOH, and water extracts. Plantarenaloside (1), 3-oxo-α-ionol β-glucoside (2), martynoside (3), acteoside (4), feruloyl gardoside (5), and ursolic acid (6) were isolated from the extract. The structures of the compounds were elucidated using 1D- and 2D-NMR and ESI-MS analyses. The extract, fractions, and pure compounds were tested in vitro for cytotoxicity (MTT), anti-inflammatory activity (NO, IL-6, and TNF-α production), wound healing (scratch test), and antioxidant capacity (DPPH, ABTS, SO). Feruloyl gardoside (20.11–58.27%) significantly reduced NO levels at concentrations of 25–100 µM. It significantly reduced IL-6 levels (40.17%) at 100 µM. Additionally, the in vivo anti-inflammatory (acetic acid-induced vascular permeability) and wound healing (incision and excision models) effects of the extracts were investigated. The findings suggest that P. indica may be considered to be a potential therapeutic option for managing inflammation and for promoting wound healing.